http://uthealth.technologypublisher.comBe the first to know about the latest inventions and technologies available from University of Texas Health Science Center At Houstonen-USThu, 09 Apr 2026 14:50:27 GMTWed, 01 Apr 2026 09:16:23 GMThttp://blogs.law.harvard.edu/tech/rssuthsch-otm@uth.tmc.eduCopyright 2026, University of Texas Health Science Center At Houston2026-0004 WEBhttp://uthealth.technologypublisher.com/technology/61052Wed, 01 Apr 2026 09:16:23 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/610522026-0038 WEBhttp://uthealth.technologypublisher.com/technology/61051Wed, 01 Apr 2026 09:15:11 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/610512025-0024 WEBhttp://uthealth.technologypublisher.com/technology/60673Wed, 04 Mar 2026 16:05:26 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/606732024-0023 WEBhttp://uthealth.technologypublisher.com/technology/60445Tumor microenvironment (TME) plays a critical role in regulating immune responses to tumors. UTHealth Houston and UTSW researchers discovered certain membrane tyrosine kinase Eph receptors, including EphA7 and EphB1, specifically bind to the immune inhibitory receptors leukocyte Ig-like receptor family B 5 (LILRB5) and result in bi-directional signaling. They further developed novel anti-LILRB5 monoclonal antibodies (mAbs) and demonstrated their therapeutic potentials in vitro and in vivo. Background Current immune checkpoint blockade therapies have been successful in treating certain types ...Mon, 16 Feb 2026 13:19:16 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/604452020-0047 WEBhttp://uthealth.technologypublisher.com/technology/60444LILRB1 expression on myeloid cells regulates both innate and adaptive immune responses. Researchers at UTHealth Houston and UTSW developed novel agonistic anti-LILRB1 monoclonal antibodies (mAbs) for autoimmune and inflammatory disease treatments, and novel antagonistic anti-LILRB1 mAbs for cancer immunotherapies. Background LILRB1, a member of the ITIM-containing LILR receptor family, plays critical roles in regulation of both innate and adaptive immunity. It is expressed on several types of immune cells, including NK cells, and acts as an immune checkpoint protein. LILRB1 expression in mye...Mon, 16 Feb 2026 13:13:29 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/604442018-0014 WEBhttp://uthealth.technologypublisher.com/technology/60443Mon, 16 Feb 2026 13:09:21 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/604432021-0005 WEBhttp://uthealth.technologypublisher.com/technology/60441Mon, 16 Feb 2026 12:55:54 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/604412017-0026 WEBhttp://uthealth.technologypublisher.com/technology/60438CAR-T cell therapy development for AML has been limited by lack of an antigen with high specificity for AML cells that is not present on normal hematopoietic stem cells. UTHealth Houston and UTSW researchers discovered that leukocyte immunoglobulin-like receptor-B4 (LILRB4) is a tumor-associated antigen highly expressed on monocytic AML cells. They further generated a novel anti-LILRB4 CAR-T cell that displays high antigen affinity and specificity, which offers a new treatment strategy for monocytic AML. Background Acute myeloid leukemia (AML) is the most common acute leukemia of adults and ...Mon, 16 Feb 2026 12:49:51 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/604382016-0029 WEBhttp://uthealth.technologypublisher.com/technology/59863Thu, 15 Jan 2026 08:41:56 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/598632024-0053 WEBhttp://uthealth.technologypublisher.com/technology/59843Description: SLC13A3 is revealed here, for the first time based on our evaluation, as a transporter for itaconate in tumor cells which plays a role in promoting tumor ferroptosis resistance, thereby weakening tumor immunity and immune checkpoint blockade (ICB). World renowned immuno-oncology leaders from UTHealth and University of Michigan (UMich) have identified a panel of monoclonal antibodies with therapeutic and diagnostic potential targeting SLC13A3 immune modulation axis, potentially pioneering the novel class of immunotherapeutics of specific antibodies in clinical trials. Background...Tue, 13 Jan 2026 11:39:58 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/598432024-0060 WEBhttp://uthealth.technologypublisher.com/technology/58769Mon, 06 Oct 2025 08:45:11 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/587692015-0059 WEBhttp://uthealth.technologypublisher.com/technology/58186Human epidermal growth factor (EGF)-like domain multiple 6 (EGFL6) was discovered in tumors and fetal tissues. Upregulated expression of EGFL6 was found in a variety of cancer cell types, such as ovarian cancer and lung cancer. Unlike VEGF, which was expressed in ovarian cancer tissues and in healing wounds, EGFL6 was expressed mainly in tumor-associated endothelial cells. UTHealth researchers and collaborators created humanized EGFL6-targeted antibodies and demonstrated that anti-EGFL6 antibodies blocked tumor angiogenesis but did not affect normal wound healing. Thus, the novel anti-EGFL6 an...Mon, 11 Aug 2025 13:42:47 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/581862025-0023 WEBhttp://uthealth.technologypublisher.com/technology/58036Thu, 17 Jul 2025 12:08:05 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/580362024-0055 WEBhttp://uthealth.technologypublisher.com/technology/55810Thu, 12 Dec 2024 11:09:47 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/558102021-0016 WEBhttp://uthealth.technologypublisher.com/technology/55343Mon, 14 Oct 2024 20:24:10 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/553432021-0047 WEBhttp://uthealth.technologypublisher.com/technology/55342Mon, 14 Oct 2024 19:48:54 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/553422022-0025 WEBhttp://uthealth.technologypublisher.com/technology/55299Tue, 08 Oct 2024 14:26:25 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/552992022-0057 WEBhttp://uthealth.technologypublisher.com/technology/53712Thu, 21 Mar 2024 10:05:54 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/537122018-0068 WEBhttp://uthealth.technologypublisher.com/technology/52958Tue, 19 Dec 2023 08:54:37 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/529582021-0043 WEBhttp://uthealth.technologypublisher.com/technology/52940Thu, 14 Dec 2023 14:49:09 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/529402021-0028 WEBhttp://uthealth.technologypublisher.com/technology/52939Thu, 14 Dec 2023 14:45:36 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/529392023-0025 WEBhttp://uthealth.technologypublisher.com/technology/52328Thu, 24 Aug 2023 08:09:09 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/523282023-0017 WEBhttp://uthealth.technologypublisher.com/technology/51298Researchers from UTHealth designed a device for developing a clot burst pressure (CBP) which can be used for direct measurement of the pressure required to dislodge a clot. More particularly, this measurement can distinguish between thrombi of hypo- and hypercoagulable states by observing differences in the CBP of conditioned groups compared to control CBP. This has the potential to be applied for a better understanding of trauma pathophysiology, thus can help direct acute care to reduce mortality rates and associated morbidities due to inappropriate resusitation. Background Trauma is the le...Tue, 06 Jun 2023 14:51:21 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/512982022-0001 WEBhttp://uthealth.technologypublisher.com/technology/50739Fri, 31 Mar 2023 07:43:34 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/507392020-0018 WEBhttp://uthealth.technologypublisher.com/technology/48816Tue, 15 Nov 2022 07:44:01 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/488162021-0018 WEBhttp://uthealth.technologypublisher.com/technology/48680Tue, 25 Oct 2022 07:30:05 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/486802019-0005 WEBhttp://uthealth.technologypublisher.com/technology/48508Thu, 22 Sep 2022 13:41:09 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/485082022-0006 WEBhttp://uthealth.technologypublisher.com/technology/47907Tue, 02 Aug 2022 08:03:02 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/479072015-0049 WEBhttp://uthealth.technologypublisher.com/technology/47223Wed, 15 Jun 2022 10:02:47 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/472232019-0016 WEBhttp://uthealth.technologypublisher.com/technology/46533R-spondins (RSPOs) are secreted proteins with critical roles in cancer development through binding to LGR4/5/6 and RNF43/ZNRF3 and potentiating Wnt signaling. UTHealth pioneering scientist engineered and fused an immunoglobin Fc domain to the mutated RSPOs (RSPO peptibodies). RSPO peptibodies can binds to LGR4/5/6 with high affinity but exhibit reduced Wnt signaling, suggesting a promising candidate for cancer treatment. Background R-spondins (RSPOs) and LGR4/5/6 form a ligand-receptor system with critical roles in normal development as well as in tumor initiation and progression. Aberrant ...Fri, 29 Apr 2022 07:26:03 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/465332018-0035 WEBhttp://uthealth.technologypublisher.com/technology/45732Tue, 18 Jan 2022 08:01:25 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/457322020-0057 WEBhttp://uthealth.technologypublisher.com/technology/45533Thu, 16 Dec 2021 13:44:45 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/455332021-0045 WEBhttp://uthealth.technologypublisher.com/technology/45532Thu, 16 Dec 2021 13:42:03 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/455322020-0033 WEBhttp://uthealth.technologypublisher.com/technology/45478Mon, 06 Dec 2021 08:50:34 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/454782019-0003 WEBhttp://uthealth.technologypublisher.com/technology/41932Tue, 22 Sep 2020 08:45:55 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/419322016-0035 WEBhttp://uthealth.technologypublisher.com/technology/41517Fri, 11 Sep 2020 10:05:44 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/415172019-0020 WEBhttp://uthealth.technologypublisher.com/technology/41301Fri, 14 Aug 2020 09:38:36 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/413012018-0001 MKGhttp://uthealth.technologypublisher.com/technology/40118 Background Cleft lip and cleft palate (CLP) is the most common birth defect in the United States, affecting more than 2,650 children born each year according to the Centers for Disease Control and Prevention. The accepted standard treatment for cleft palate is autologous bone grafting, which provides a stable repair but is invasive and can be followed by potential complications of graft exposure and loss. In addition, autologous bone grafting is subject to donor site morbidity including infection, long-term pain and/or nerve damage that lead to the need of additional surgeries. Another strat...Tue, 02 Jun 2020 11:59:32 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/401182020-0035 WEBhttp://uthealth.technologypublisher.com/technology/39857Mon, 11 May 2020 13:33:58 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/398572018-0031 WEBhttp://uthealth.technologypublisher.com/technology/39076BackgroundLeptin is a hormone produced by adipocytes and is elevated in obesity. The congenital lack of leptin results in obesity and the metabolism field widely accepts the concept. Upon cloning of the leptin gene, the original hope was that leptin would act as a break for further food intake and a trigger to increase energy expenditure. The hope was that the injection of recombinant leptin would act as an effective weight loss mechanism. However, these hopes were quickly disappointed, since obese individuals have high leptin levels, but these individual are leptin resistant. Not even the inj...Thu, 05 Mar 2020 09:18:59 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/390762018-0061 WEBhttp://uthealth.technologypublisher.com/technology/38554Fri, 14 Feb 2020 11:20:38 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/385542019-0034 WEBhttp://uthealth.technologypublisher.com/technology/37881Wed, 15 Jan 2020 08:44:48 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/378812013-0024WEBhttp://uthealth.technologypublisher.com/technology/37700Wed, 08 Jan 2020 08:27:54 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/377002019-0060 WEBhttp://uthealth.technologypublisher.com/technology/35512Fri, 16 Aug 2019 13:38:17 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/355122018-0051 WEBhttp://uthealth.technologypublisher.com/technology/35474Wed, 14 Aug 2019 07:59:39 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/354742016-0013 WEBhttp://uthealth.technologypublisher.com/technology/35001Tue, 16 Jul 2019 09:59:17 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/350012012-0015 WEBhttp://uthealth.technologypublisher.com/technology/34711Wed, 26 Jun 2019 15:59:04 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/347112018-0050 WEBhttp://uthealth.technologypublisher.com/technology/31255Background Syphilis is a multistage sexually transmitted infection of world-wide importance, with an estimated 5.6 million new cases per year. Treponema pallidum, the causative agent of syphilis, was first identified by Schaudinn and Hoffman in 1905, but in the past researchers have been unable to maintain T. pallidum viability or multiplication beyond 12 to 18 days. The inability to culture these organisms continuously in vitro has necessitated their propagation in rabbits for use in research and the production of antigens for serodiagnostic tests. Discovery UTHealth researchers have devel...Wed, 06 Feb 2019 15:33:06 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/312552018-0056 WEBhttp://uthealth.technologypublisher.com/technology/28554Fri, 24 Aug 2018 08:30:50 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/285542017-0055 WEBhttp://uthealth.technologypublisher.com/technology/28465With the availability of genotyping data of very large samples, there is an increasing need for tools that can efficiently identify genetic relationships among all individuals in the sample. One fundamental measure of genetic relationship of a pair of individuals is identity by descent (lBD), chromosomal segments that are shared among two individuals due to common ancestry. However, the efficient identification of lBD segments among a large number of genotyped individuals is a challenging computational problem. Some methods, such as GERMLINE, use fast dictionary lookup of short seed sequence m...Mon, 13 Aug 2018 12:26:00 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/2846520170050WEBhttp://uthealth.technologypublisher.com/technology/27051Thu, 01 Feb 2018 11:02:27 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/270512017-0034 WEBhttp://uthealth.technologypublisher.com/technology/26975Fri, 26 Jan 2018 11:35:01 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/269752014-0045 WEBhttp://uthealth.technologypublisher.com/technology/26605Mon, 20 Nov 2017 14:43:22 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/266052011-0009 WEBhttp://uthealth.technologypublisher.com/technology/26392Thu, 12 Oct 2017 12:41:49 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/263922014-0055 WEBhttp://uthealth.technologypublisher.com/technology/25072Fri, 14 Apr 2017 07:51:23 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/250722013-0034WEBhttp://uthealth.technologypublisher.com/technology/21703Thu, 07 Apr 2016 14:43:50 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/217032008-0006 WEBhttp://uthealth.technologypublisher.com/technology/20147Mon, 24 Aug 2015 09:40:43 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/201472011-0015 WEBhttp://uthealth.technologypublisher.com/technology/20083Wed, 05 Aug 2015 11:23:41 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/20083